Table S4 The difference in eGFR decline from baseline between the two groups per 12 weeks in individuals with complete baseline data

|  |  |  |  |
| --- | --- | --- | --- |
| TAF vs. ETV | Model 1 | Model 2 | Model 3 |
| β (95% CI) | *P* value | β (95% CI) | *P* value | β (95% CI) | *P* value |
| Baseline eGFR ≥ 90 ml/min/1.73m2 |  |  |  |  |  |  |
| Overall | 0.44 (0.17–0.71) | 0.001 | 0.42 (0.14–0.69) | 0.003 | 0.40 (0.12–0.67) | 0.005 |
| Female | 0.17 (-0.29–0.63) | 0.466 | 0.13 (-0.35–0.60) | 0.605 | 0.14 (-0.33–0.61) | 0.561 |
| Male | 0.41 (0.08–0.74) | 0.014 | 0.40 (0.06–0.73) | 0.021 | 0.38 (0.05–0.71) | 0.025 |
| Age < 35 years | 0.40 (-0.04–0.84) | 0.072 | 0.37 (-0.08–0.82) | 0.106 | 0.36 (-0.08–0.80) | 0.109 |
| 35 years ≤ age ≤ 65 years | 0.49 (0.14–0.84) | 0.006 | 0.47 (0.11–0.83) | 0.010 | 0.47 (0.11–0.82) | 0.010 |
| Baseline eGFR < 90 ml/min/1.73m2 |  |  |  |  |  |  |
|  | 0.23 (-0.45–0.91) | 0.514 | 0.15 (-0.58–0.87) | 0.693 | 0.18 (-0.53–0.88) | 0.627 |

Model 1: unadjusted model.

Model 2: adjusted for all variables.3

Model 3: adjusted for the variables of which *p* < 0.05 in Model 2. **1.** Baseline eGFR ≥ 90 ml/min/1.73m2 subgroup: **1.1** overall: adjusted for diuretics, age, sex, baseline eGFR, and HBeAg positivity; **1.2** Female groups: adjusted for age, MASLD, baseline eGFR, DB, and ALB. **1.3** Male group: adjusted for age, diuretics, baseline eGFR, and HBeAg positivity; **1.4** age < 35 years groups: adjusted for baseline eGFR. **1.5** 35 years ≤ age ≤ 65 years group: adjusted for diuretics, baseline eGFR, and DB. **2.** Baseline eGFR < 90 ml/min/1.73m2 subgroup: adjusted for age, cirrhosis, and baseline eGFR.